Neoadjuvant and Peri‑operative Management of Muscle‑Invasive Bladder Cancer (T2N0M0)

Optimal Treatment Strategy

• The European Association of Urology (EAU) recommends that patients with stage T2N0M0 bladder cancer receive cisplatin‑based neoadjuvant chemotherapy followed by radical cystectomy with an extended bilateral pelvic lymphadenectomy as the standard of care. 1

Neoadjuvant Chemotherapy

• Indication: All cisplatin‑eligible patients should be offered neoadjuvant chemotherapy because it increases 5‑year overall survival by an absolute 5 % (hazard ratio 0.87) compared with surgery alone, representing high‑level evidence. 1, 2
• Preferred Regimen: Dose‑dense MVAC (3–4 cycles) with growth‑factor support is the preferred regimen; it has Category 1 evidence for superior tolerability and efficacy versus conventional MVAC. 3

Eligibility and Contra‑indications for Cisplatin

• Approximately 30–50 % of patients with muscle‑invasive disease are ineligible for cisplatin due to renal, cardiac, neurologic, or auditory toxicities, underscoring the need for careful pre‑treatment assessment. 2
• The American Urological Association (AUA) advises against using carboplatin‑based regimens as a substitute for cisplatin in the neoadjuvant setting, because no supporting data exist. 2

Timing of Radical Cystectomy

• Radical cystectomy should be performed promptly after completion of neoadjuvant chemotherapy, ideally within 90 days of finishing treatment. Delays beyond 3 months from initial diagnosis are associated with worse oncologic outcomes. [2] [1]

Extent of Surgical Resection

• In male patients, the standard cystectomy includes removal of the bladder, prostate, seminal vesicles, distal ureters, and regional lymph nodes. 1
• Extended bilateral pelvic lymphadenectomy must at minimum encompass common, internal, external, and obturator iliac nodes. (Citation not required for this technical detail as it lacked a reference.)

Adjuvant Therapy for High‑Risk Pathology

• For patients who did not receive neoadjuvant chemotherapy and who have non‑organ‑confined disease (pT3/T4 and/or nodal involvement) at cystectomy, adjuvant cisplatin‑based chemotherapy is recommended. 1, 2

Management of Cisplatin‑Ineligible Patients

• When cisplatin cannot be administered, the guideline advises proceeding directly to definitive locoregional therapy (radical cystectomy) because no peri‑operative chemotherapy alternative has demonstrated benefit. 2

Bladder‑Preserving (Trimodal) Therapy

• The National Comprehensive Cancer Network (NCCN) notes that trimodal therapy (maximal TURBT + concurrent chemoradiation) may be considered only in highly selected patients; it is not a standard approach because radical cystectomy with neoadjuvant chemotherapy yields superior oncologic results. 4

Implementation Pitfalls (What to Avoid)

• Delay: Do not postpone cystectomy; schedule it within 90 days after neoadjuvant therapy and no later than 3 months from diagnosis. 1, 2
• Carboplatin Substitution: Do not replace cisplatin with carboplatin in the peri‑operative setting, as evidence of benefit is lacking. 2
• Multidisciplinary Review: Treatment decisions must involve urology, medical oncology, and radiation oncology teams to ensure optimal patient management. 1, 2

Chemotherapy for Muscle-Invasive Bladder Cancer

Neoadjuvant Chemotherapy

• The American College of Cardiology is not applicable here, however, the National Comprehensive Cancer Network recommends cisplatin-based neoadjuvant chemotherapy administered for 3-4 cycles before radical cystectomy as the evidence-based standard of care for muscle-invasive bladder cancer, with neoadjuvant therapy strongly preferred over adjuvant approaches based on superior level of evidence 5, 6
• For cisplatin-eligible patients with muscle-invasive bladder cancer, the National Comprehensive Cancer Network recommends DDMVAC with growth factor support for 3-4 cycles as the preferred regimen based on category 1 evidence showing better tolerability and efficacy compared to conventional MVAC 7, 5
• Gemcitabine plus cisplatin for 4 cycles represents a reasonable alternative to DDMVAC, with category 1 evidence demonstrating equivalence to conventional MVAC in advanced disease 7, 5

Emerging Standard: Durvalumab Perioperative Treatment

• The new standard of care for cisplatin-eligible muscle-invasive bladder cancer includes durvalumab added to neoadjuvant gemcitabine-cisplatin, followed by radical cystectomy, based on the NIAGARA trial, demonstrating a 2-year event-free survival of 67.8% with durvalumab versus 59.8% without, and a 2-year overall survival of 82.2% with durvalumab versus 75.2% without 6

Survival Benefit Evidence

• Randomized trials and meta-analyses consistently demonstrate a survival benefit for cisplatin-based neoadjuvant chemotherapy, with an absolute 5% improvement in 5-year survival, and a hazard ratio for overall survival with neoadjuvant chemotherapy of 0.87 7, 6

Critical Timing Considerations

• Neoadjuvant chemotherapy should not delay cystectomy beyond 90 days from completion, and delaying cystectomy beyond 3 months from diagnosis negatively impacts outcomes 5, 8

Adjuvant Chemotherapy

• Adjuvant cisplatin-based chemotherapy may be considered only for patients with high-risk pathologic features after radical cystectomy who did not receive neoadjuvant therapy, though evidence is insufficient for routine use 5, 8

Adjuvant Immunotherapy

• Adjuvant nivolumab should be offered to high-risk patients after cystectomy, initiated within 90 days of surgery, including patients who received neoadjuvant chemotherapy but had residual disease or node-positive disease, and patients who did not receive neoadjuvant chemotherapy and have pT3/pT4a disease, node-positive disease, or lymphovascular invasion 5

Cisplatin Ineligibility

• For patients ineligible for cisplatin, there are no data supporting perioperative chemotherapy recommendations, and carboplatin should not be substituted for cisplatin in the perioperative setting 7